Evidence implicating genetic factors in PTD has been summarized elsewhere. It includes the tendency of PTD to recur and familial aggregation. A prior history of PTD is one of the most powerful risk factors for future PTD. Recurrent PTD contributes to a sizable proportion of all PTDs. While risk of recurrence is consistent with a [...]
African Americans have 60% higher risk for preterm (<37 weeks gestation) delivery (PTD) birth and three times the risk for extreme (<28 weeks gestation) PTD (1.8%) as whites (0.5%)J Eighty percent of the racial disparity in neonatal mortality is attributable to PTD of infants less than 1,000 g. Traditional socioeconomic and behavioral risk factors do [...]
This was the first randomized study to directly compare OROS MPH and atomoxetine in African-American children. Response in this population was consistent with that observed in the overall population. Both treatments demonstrated significant improvement from baseline; however, improvements noted in the OROS MPH group were consistently greater than those observed in the atomoxetine group. Differences [...]
A total of 1,323 patients were enrolled in this study; of these, 183 were African-American (OROS MPH: n=125, ato-moxetine: n=58). The mean age of the total African-American group was approximately nine years, and most (87%) patients were male (Table 1). The treatment groups were well matched with regard to baseline disease characteristics. Adherence to study [...]
Patients
Eligible children were 6-12 years of age with a diagnosis of ADHD based on psychiatric history and a review of the DSM-IV diagnostic checklist. Children must have scored >24 on the ADHD-RS at screening and must have been rated “moderately ill” or worse on the CGI-SI. Newly diagnosed treatment-naive patients and previously diagnosed patients who [...]
The most studied and most often used stimulant medication for attention-deficit/hyperactivity disorder (ADHD) is methylphenidate (MPH). By 1996, there were 133 randomized, controlled trials describing the treatment of ADHD with MPH. However, MPH has a short duration of effect that results in a need for multiple daily dosing. Therefore, several long-acting formulations have been developed [...]
The results indicate that there was little difference between black and white respondents in knowledge of the Tuskegee study. Most people were unaware of the Tuskegee study, with only approximately two-fifths of both black and white participants indicating they had heard of it. Among those that were aware of the study, there was limited accurate [...]
